Table 1.
Demographic and clinical characteristics of patients with generalized refractory myasthenia gravis transitioned from IVIg to eculizumab.
| Patient No. | Sex | Age (years) | Time since MG diagnosis (years) | Thymectomy | Previous medication | Concomitant medication* | MGCS before eculizumab | Change in MGCS after 6 weeks’ eculizumab treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 62 | 5 | Yes | IVIg Mycophenolate mofetil Prednisone Plasmapheresis Methotrexate |
IVIg 2 g/kg/month Mycophenolate mofetil 1500 mg BID Prednisone 40 mg/day Methotrexate 15 mg/week |
29 | −17 |
| 2 | F | 74 | 2 | No | Prednisone Mycophenolate mofetil IVIg |
Prednisone 20 mg/day Mycophenolate mofetil 1500 mg BID IVIg 2 g/kg/month |
13 | −7 |
| 3 | M | 71 | 9 | No | Plasmapheresis IVIg Azathioprine Mycophenolate mofetil Methotrexate |
IVIg 2 g/kg/month Methotrexate 20 mg/week |
23 | −9 |
| 4 | F | 78 | 17 | No | Mycophenolate mofetil Methotrexate Prednisone IVIg Azathioprine |
IVIg 2 g/kg/month Azathioprine 150 mg/day |
21 | −6 |
| 5 | F | 34 | 11 | Yes | Mycophenolate mofetil IVIg Rituximab Methotrexate Cyclosporine |
Mycophenolate mofetil 1500 mg BID IVIg 2 g/kg/month Cyclosporine 25 mg BID |
25 | −7 |
| 6 | M | 74 | 10 | No | IVIg Mycophenolate mofetil Plasmapheresis |
IVIg 2 g/kg/month Mycophenolate mofetil 1000 mg BID |
17 | −8 |
| 7 | F | 68 | 17 | Yes | Prednisone Mycophenolate mofetil Cyclosporine IVIg Plasmapheresis |
Mycophenolate mofetil 1500 mg BID Cyclosporine 100 mg BID IVIg 2 g/kg/month |
20 | −10 |
| 8 | M | 72 | 7 | Yes | Prednisone IVIg Mycophenolate mofetil Plasmapheresis |
Prednisone 30 mg/day IVIg 2 g/kg/month Mycophenolate mofetil 1000 mg BID |
21 | −11 |
| 9 | F | 30 | 4 | Yes | IVIg Prednisone Mycophenolate mofetil Methotrexate |
IVIg 2 g/kg/month Prednisone 20 mg/day Mycophenolate mofetil 1500 mg BID Methotrexate 10 mg/week |
11 | −4 |
| 10 | F | 64 | 3 | No | Prednisone Mycophenolate mofetil IVIg Methotrexate Cyclosporine |
Prednisone 12.5 mg/day Mycophenolate mofetil 1500 mg BID IVIg 2 g/kg/month Cyclosporine 75 mg BID |
17 | −8 |
| 11 | M | 66 | 3 | Yes | IVIg Mycophenolate mofetil |
IVIg 2 g/kg/month Mycophenolate mofetil 1500 mg BID |
24 | −7 |
| 12 | M | 71 | 4 | No | Mycophenolate mofetil IVIg Methotrexate |
Mycophenolate mofetil 1000 mg BID IVIg 2 g/kg/month Methotrexate 20 mg/week |
20 | −7 |
| 13 | M | 75 | 6 | No | Prednisone Azathioprine Mycophenolate mofetil IVIg Methotrexate Cyclosporine |
Prednisone 30 mg/day IVIg 2 g/kg/month Cyclosporine 75 mg BID |
25 | −10 |
*
Information on IVIg refers to the last dose that patients received before being transitioned to eculizumab; all other drugs were continued during eculizumab treatment. BID – twice daily; F – female; IVIg – intravenous immunoglobulin; M – male; MG – myasthenia gravis; MGCS – Myasthenia Gravis Composite Score.